Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 13289

1.

The elderly and direct antiviral agents: Constraint or challenge?

Fabrizio C, Saracino A, Scudeller L, Milano E, Dell'Acqua R, Bruno G, Lo Caputo S, Monno L, Milella M, Angarano G.

Dig Liver Dis. 2017 Jun 1. pii: S1590-8658(17)30896-4. doi: 10.1016/j.dld.2017.05.019. [Epub ahead of print]

PMID:
28651903
2.

[Personalized treatment of viral hepatitis of the present and the future : Hepatitis B, C, delta, and E].

Bartenschlager R, Cornberg M, Pietschmann T.

Internist (Berl). 2017 Jun 19. doi: 10.1007/s00108-017-0262-8. [Epub ahead of print] Review. German.

PMID:
28631044
3.

Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C.

Nagata H, Nakagawa M, Asahina Y, Sato A, Asano Y, Tsunoda T, Miyoshi M, Kaneko S, Otani S, Kawai-Kitahata F, Murakawa M, Nitta S, Itsui Y, Azuma S, Kakinuma S, Nouchi T, Sakai H, Tomita M, Watanabe M; Ochanomizu Liver Conference Study Group.

J Hepatol. 2017 Jun 13. pii: S0168-8278(17)32070-6. doi: 10.1016/j.jhep.2017.05.028. [Epub ahead of print]

PMID:
28627363
4.

On-treatment decrease of NKG2D correlates to early emergence of clinically evident hepatocellular carcinoma after interferon-free therapy for chronic hepatitis C.

Chu PS, Nakamoto N, Taniki N, Ojiro K, Amiya T, Makita Y, Murata H, Yamaguchi A, Shiba S, Miyake R, Katayama T, Ugamura A, Ikura A, Takeda K, Ebinuma H, Saito H, Kanai T.

PLoS One. 2017 Jun 15;12(6):e0179096. doi: 10.1371/journal.pone.0179096. eCollection 2017.

5.

Favouring modulation of circulating lipoproteins and lipid loading capacity by direct antiviral agents grazoprevir/elbasvir or ledipasvir/sofosbuvir treatment against chronic HCV infection.

Sun HY, Cheng PN, Tseng CY, Tsai WJ, Chiu YC, Young KC.

Gut. 2017 Jun 14. pii: gutjnl-2017-313832. doi: 10.1136/gutjnl-2017-313832. [Epub ahead of print]

PMID:
28615303
6.

Is elimination of hepatitis C from the UK by 2030 a realistic goal?

Gelson W, Alexander G.

Br Med Bull. 2017 Jun 9:1-9. doi: 10.1093/bmb/ldx017. [Epub ahead of print]

PMID:
28605444
7.

Pegylated interferon plus ribavirin combination therapy in postliver transplant recipients with recurrent hepatitis C virus infection.

Lin TY, Yeh ML, Huang CI, Chen YL, Dai CY, Huang JF, Lin ZY, Chen SC, Huang CF, Yu ML, Chuang WL.

Kaohsiung J Med Sci. 2017 Jun;33(6):284-289. doi: 10.1016/j.kjms.2017.03.007. Epub 2017 Apr 20.

8.

Is There a Relationship Between Treatment With Direct Antiviral Agents for HCV Infection and the Development of Malignancies?

Saadi T, Khoury J.

J Clin Gastroenterol. 2017 Jun 5. doi: 10.1097/MCG.0000000000000853. [Epub ahead of print]

PMID:
28590324
9.

Direct-acting antiviral agents improved nephrotic syndrome associated with refractory pleural effusion and ascites caused by hepatitis C virus-related nephropathy: a case report.

Yamato M, Arai K, Takatori H, Shimakami T, Yamashita T, Sakai Y, Yamashita T, Mizukoshi E, Honda M, Kaneko S.

Nihon Shokakibyo Gakkai Zasshi. 2017;114(6):1031-1038. doi: 10.11405/nisshoshi.114.1031.

PMID:
28579587
10.

Dynamic Changes of the Frequency of Classic and Inflammatory Monocytes Subsets and Natural Killer Cells in Chronic Hepatitis C Patients Treated by Direct-Acting Antiviral Agents.

Ning G, Li YT, Chen YM, Zhang Y, Zeng YF, Lin CS.

Can J Gastroenterol Hepatol. 2017;2017:3612403. doi: 10.1155/2017/3612403. Epub 2017 May 8.

11.

[Determination of drug resistance mutations of NS3 inhibitors in chronic hepatitis C patients infected with genotype 1].

Şanlıdağ T, Sayan M, Akçalı S, Kasap E, Buran T, Arıkan A.

Mikrobiyol Bul. 2017 Apr;51(2):145-155. Turkish.

PMID:
28566078
12.

Identification of groups with poor cost-effectiveness of peginterferon plus ribavirin for naïve hepatitis C patients with a real-world cohort and database.

Tsai PC, Liu TW, Tsai YS, Ko YM, Chen KY, Lin CC, Huang CI, Liang PC, Lin YH, Hsieh MY, Hou NJ, Huang CF, Yeh ML, Lin ZY, Chen SC, Dai CY, Chuang WL, Huang JF, Yu ML.

Medicine (Baltimore). 2017 Jun;96(22):e6984. doi: 10.1097/MD.0000000000006984.

13.

Increased incidence of liver cancer after successful DAA treatment of chronic hepatitis C: Fact or fiction?

Alberti A, Piovesan S.

Liver Int. 2017 Jun;37(6):802-808. doi: 10.1111/liv.13390.

PMID:
28544696
14.

[Effectiveness of second-generation direct-acting antivirals in chronic hepatitis C].

Juanbeltz Zurbano R, Zozaya Urmeneta JM, Repáraz Padrós J, Castilla Catalán J, Sarobe Carricas MT, Úriz-Otano JI, Gracia Ruiz de Alda M, San Miguel Elcano R.

An Sist Sanit Navar. 2017 Apr 30;40(1):57-66. doi: 10.23938/ASSN.0006. Spanish.

15.

Hepatitis B virus reactivation after effective sofosbuvir and ribavirin treatment in a patient with occult hepatitis B virus infection.

Odolini S, Lanza P, Spinetti A, Zaltron S, Urbinati L, Vavassori A, Nasta P, Festa E, Gargiulo F, Rodella A, Caruso A, Casari S, Castelli F, Viganò M.

New Microbiol. 2017 May 17;40(3). [Epub ahead of print]

16.

A case of rapid amelioration of hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis treated by interferon-free directly acting antivirals for HCV in the absence of immunosuppressant.

Obata F, Murakami T, Miyagi J, Ueda S, Inagaki T, Minato M, Ono H, Nishimura K, Shibata E, Tamaki M, Yoshimoto S, Kishi F, Kishi S, Matsuura M, Nagai K, Abe H, Doi T.

CEN Case Rep. 2017 May;6(1):55-60. doi: 10.1007/s13730-016-0244-z. Epub 2016 Nov 21.

17.

Hepatitis B virus infection and alcohol consumption.

Iida-Ueno A, Enomoto M, Tamori A, Kawada N.

World J Gastroenterol. 2017 Apr 21;23(15):2651-2659. doi: 10.3748/wjg.v23.i15.2651. Review.

18.

[Recent advances in the treatment of hepatitis C in 2016].

Luo BF, Wei L.

Zhonghua Gan Zang Bing Za Zhi. 2017 Mar 20;25(3):175-180. doi: 10.3760/cma.j.issn.1007-3418.2017.03.004. Chinese.

PMID:
28482403
19.

[Clinical significance of drug resistance-associated mutations in treatment of hepatitis C with direct-acting antiviral agents].

Li Z, Chen ZW, Ren H, Hu P.

Zhonghua Gan Zang Bing Za Zhi. 2017 Mar 20;25(3):170-174. doi: 10.3760/cma.j.issn.1007-3418.2017.03.003. Chinese.

PMID:
28482402
20.

Hepatitis B Virus Reactivation in Patients Receiving Interferon-Free Direct-Acting Antiviral Agents for Chronic Hepatitis C Virus Infection.

Liu CH, Liu CJ, Su TH, Fang YJ, Yang HC, Chen PJ, Chen DS, Kao JH.

Open Forum Infect Dis. 2017 Feb 11;4(1):ofx028. doi: 10.1093/ofid/ofx028. eCollection 2017 Winter.

Supplemental Content

Loading ...
Support Center